SCHEMBL16489291

SCHEMBL16489291

CCc1ccc(/C(N)=N/O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.57
GAA P10253 2/20 0.55
RAB9A P51151 2/20 0.55
LMNA P02545 3/20 0.50
PLAU P00749 1/20 0.50
NPC1 O15118 1/20 0.50
TP53 P04637 1/20 0.50
MAPT P10636 1/20 0.50
ALOX15 P16050 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ALDH1A1 P00352 2/20 0.48
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
KDM1A O60341 1/20 0.46
HDAC1 Q13547 3/20 0.44
HDAC2 Q92769 3/20 0.44
IDO1 P14902 2/20 0.44
PLK1 P53350 1/20 0.44
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17735999 1.00 SMN1; SMN2 (0.57) SMN1; SMN2GAARAB9ALMNAPLAU
SCHEMBL15186451 0.83 GAA (0.56) GAARAB9ALMNANPC1TP53
SCHEMBL14291952 0.83 SMN1; SMN2 (0.57) SMN1; SMN2GAARAB9APLAUALDH1A1
SCHEMBL20713868 0.83 SMN1; SMN2 (0.57) SMN1; SMN2GAARAB9APLAUALDH1A1
SCHEMBL21215222 0.81 KDM1A (0.60) GAARAB9ALMNANPC1TP53
SCHEMBL320862 0.80 PRSS1 (0.56) GAARAB9ALMNANPC1TP53
SCHEMBL320861 0.80 PRSS1 (0.56) GAARAB9ALMNANPC1TP53
SCHEMBL4253161 0.80 LOXL2 (0.56) GAARAB9ALMNANPC1TP53
SCHEMBL5154701 0.80 LOXL2 (0.56) GAARAB9ALMNANPC1TP53
SCHEMBL4253164 0.80 LOXL2 (0.56) GAARAB9ALMNANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 US disclosed
WO-2021254919-A1 SELECTIVE TMPRSS2 INHIBITORS AND MEDICAL USE THEREOF MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-12-23 WO disclosed
EP-3925667-A1 SELECTIVE TMPRSS2 INHIBITORS AND MEDICAL USE THEREOF Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-12-22 EP disclosed
EP-3466961-A1 PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF Li, Min (US) 2019-04-10 EP disclosed
WO-2017096301-A1 ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1) DENALI THERAPEUTICS INC. (US) 2017-06-08 WO disclosed
US-9266828-B2 Inhibitors of Furin and other pro-protein convertases SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2016-02-23 US disclosed
US-20150073054-A1 INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2015-03-12 US disclosed
US-20150051138-A1 INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 SMN1; SMN2 1476/4885GAA 1678/4885RAB9A 2027/4885
US-20150051138-A1 INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES FURIN, PREP, PCSK6 SMN1; SMN2 4554/4885GAA 1644/4885RAB9A 517/4885
US-20150073054-A1 INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES FURIN, PREP, PCSK6 SMN1; SMN2 4554/4885GAA 1644/4885RAB9A 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.